- Research article
- Open Access
c-MycERTAM transgene silencing in a genetically modified human neural stem cell line implanted into MCAo rodent brain
BMC Neurosciencevolume 10, Article number: 86 (2009)
The human neural stem cell line CTX0E03 was developed for the cell based treatment of chronic stroke disability. Derived from fetal cortical brain tissue, CTX0E03 is a clonal cell line that contains a single copy of the c-mycERTAM transgene delivered by retroviral infection. Under the conditional regulation by 4-hydroxytamoxifen (4-OHT), c-mycERTAM enabled large-scale stable banking of the CTX0E03 cells. In this study, we investigated the fate of this transgene following growth arrest (EGF, bFGF and 4-OHT withdrawal) in vitro and following intracerebral implantation into a mid-cerebral artery occluded (MCAo) rat brain. In vitro, 4-weeks after removing growth factors and 4-OHT from the culture medium, c-mycERTAM transgene transcription is reduced by ~75%. Furthermore, immunocytochemistry and western blotting demonstrated a concurrent decrease in the c-MycERTAM protein. To examine the transcription of the transgene in vivo, CTX0E03 cells (450,000) were implanted 4-weeks post MCAo lesion and analysed for human cell survival and c-mycERTAM transcription by qPCR and qRT-PCR, respectively.
The results show that CTX0E03 cells were present in all grafted animal brains ranging from 6.3% to 39.8% of the total cells injected. Prior to implantation, the CTX0E03 cell suspension contained 215.7 (SEM = 13.2) copies of the c-mycERTAM transcript per cell. After implantation the c-mycERTAM transcript copy number per CTX0E03 cell had reduced to 6.9 (SEM = 3.4) at 1-week and 7.7 (SEM = 2.5) at 4-weeks. Bisulfite genomic DNA sequencing of the in vivo samples confirmed c-mycERTAM silencing occurred through methylation of the transgene promoter sequence.
In conclusion the results confirm that CTX0E03 cells downregulated c-mycERTAM transgene expression both in vitro following EGF, bFGF and 4-OHT withdrawal and in vivo following implantation in MCAo rat brain. The silencing of the c-mycERTAM transgene in vivo provides an additional safety feature of CTX0E03 cells for potential clinical application.
Stem cell therapy is a facet of regenerative medicine that aims to ameliorate the damage caused to the brain by the grafting of healthy "reparative" cells. Pioneering studies implanting mouse neural stem cells (NSCs) into the brains of stroke animals have demonstrated significant recovery in motor and cognitive tests [1–5]. These findings provide a rational approach to the development of a cell based therapy for ischemic stroke. A substantial and consistent supply of allogeneic NSCs is required in order to treat a large patient population. Unfortunately, human NSCs are somatic stem cells and susceptible to genetic and phenotypic changes and loss of biological activity following extensive tissue culture expansion [6–8].
Immortalization of NSCs overcomes their restricted expansion potential. The myc proto-oncogene has proven a successful tool for immortalization of NSCs [9–16]. In these research applications, both v- and c-myc promote consistent and enhanced tissue culture expansion of human NSCs while maintaining a stable karyotype and retaining biological activity. The c-mycERTAM technology has proven to be as successful in generating immortalized neural stem cell lines as c-myc alone [17–20]. The c-mycERTAM transgene is better suited as an immortalizing agent for clinical applications because c-Myc protein function is conditional on the presence of the tamoxifen metabolite, 4-hydroxytamoxifen (4-OHT). The translated c-MycERTAM recombinant protein is a conjugation of human c-Myc and modified mouse estradiol receptor (ER) and is present as an inactive monomer in the cytosol of the cell. When added to the tissue culture medium, 4-OHT specifically binds to the ER moiety causing the c-MycERTAM protein to dimerize and subsequently translocate to the cell nucleus where c-Myc is active as a transcription factor .
CTX0E03 is a human NSC line that was derived using c-mycERTAM technology and showed recovery in sensorimotor deficits following grafting in MCAo rodent brain [19, 22]. One copy of the c-mycERTAM transgene is integrated into the CTX0E03 cell genome (chromosome 13) under the cytomegalovirus (CMV) immediate early promoter . We have shown that the c-mycERTAM transgene is expressed in proliferating CTX0E03 cell cultures in vitro; however, the expression of this transgene following the grafting of CTX0E03 cells in vivo was not characterized. Although neoplasm formation has never been observed with CTX0E03 cells in multiple pre-clinical studies, this information would nonetheless be important in assessing the inherent risk of using a genetically modified cell line for clinical applications.
Analysis of transgene expression following implantation of genetically modified cells is challenging because of the relatively small proportion of implanted cells compared to the host. Using a fluorescent reporter transgene, the CMV promoter has been shown to undergo silencing in grafted hematopoietic cells in vivo . In another example, Lee et al. demonstrated by immunohistochemistry (IHC) that v-myc was silenced following intracerebral implantation of immortalized HBF1.3 cells . Unfortunately, these methodologies were not appropriate for our application. The c-mycERTAM transgene in CTX0E03 cells does not contain a fluorescent reporter that could be monitored. With respect to IHC, we were concerned it would be inconclusive due to the unknown sensitivity and potential cross-reactivity of the antibodies. Furthermore, IHC was ruled out since the analysis would be limited to a finite number of sections and would not encompass all cells present in the graft.
In this study, we developed a novel and sensitive method that is able to analyze absolute gene expression within human genetically modified cells grafted into rodent brain. This method used the human specific Alu genomic sequence to detect and quantify CTX0E03 cells grafted within the rodent brain background [25, 26]. Absolute quantification of c-mycERTAM transcription made it possible to calculate the number of c-mycERTAM transcript copies per CTX0E03 cell. Using this methodology, c-mycERTAM transgene silencing was shown following grafting of CTX0E03 cells into MCAo rat brain. Although not intentionally incorporated into the design technology of c-mycERTAM, silencing of the CMV transgene promoter in vivo demonstrates an additional safety feature of this technology and of the CTX0E03 cells.
Alu and c-mycERTAM assay design
The analysis of the c-mycERTAM transcript expression per CTX0E03 cell, both in vivo and in vitro, was dependent upon the ability to sequentially purify genomic DNA (gDNA) and RNA from the same biological sample using the All DNA/RNA Kit (Qiagen). The gDNA preparation yielded one single band by agarose gel electrophoresis with no evidence of degradation or contaminating RNA (Figure 1A). The RNA preparation yielded the expected 28S and 18S bands, again with no degradation or DNA contamination visible (Figure 1B). Standard curves were then generated to determine: 1) the number of CTX0E03 cells present in a gDNA sample by Alu qPCR (Figure 1C); and 2) the number of c-mycERTAM transcripts present in a retro-transcribed RNA reaction sample (Figure 1D). The Alu sequence assay could reproducibly detect human CTX0E03 gDNA with as few as one CTX0E03 cell per reaction; whereas, the c-mycERTAM assay could detect as few as 10 copies per reaction.
Validation of Alu and c-mycERTAM assays
The Alu sequence and c-mycERTAM transcription assays were developed in the presence of rat brain gDNA or cDNA, as described in the Methods. These experiments involved mixing purified CTX0E03 DNA/cDNA with purified rat brain DNA/cDNA. However, in order to verify that CTX0E03 cells grafted in rat brain could be processed and analysed effectively together a positive control experiment was carried out. This experiment consisted of harvesting and processing the rat brain tissue immediately after a 6 μl injection of CTX0E03 cells was delivered. It was determined by counting using a haemocytometer that the cell suspension prior to delivery contained 46,600 cells/μl – i.e. total of 279,600 cells were present in 6 μl loaded into the syringe. By Alu sequence analysis, the injected rat brain tissue sections contained an average of 241,116 (SEM = 15,487) CTX0E03 cells (Figure 1F). The measured number of CTX0E03 cells is within the range expected. Analysis of the total RNA isolated from these samples showed CTX0E03 cells to express on average 236.9 (SEM = 7.8) c-mycERTAM transcript copies per cell (Figure 1G). Control CTX0E03 cells measured in culture were shown to have a similar value of 242.3 (SEM = 47.8) c-mycERTAM transcript copies per cell.
CTX0E03 cell detection and quantification in vivo
Four weeks after the MCAo, a total of 450,000 CTX0E03 cells were implanted bilaterally into the putamen. The rats were sacrificed 1-week or 4-weeks post-implantation, their brains were removed and sections encompassing the injection tracts were dissected and snap frozen in liquid nitrogen. The Alu and c-mycERTAM assays were then carried out on the gDNA and cDNA isolated from each tissue section, respectively. CTX0E03 cells were detected in all implanted animals at both time points, with a range of 28,151 to 179,184 CTX0E03 cells detected per brain. The total number of CTX0E03 cells detected, per rat brain, is shown at 1-week (Figure 2A) and 4-weeks (Figure 2B) post-implantation. An aliquot of the CTX0E03 cell suspension prepared for implantation was retained and used to determine the pre-implantation c-mycERTAM transcript copy number. The average c-mycERTAM transcription level for the three CTX0E03 cell suspensions prepared in this study was found to be 215.7 (SEM = 13.2) copies per cell (Figure 2C). This is compared to the population of CTX0E03 cells detected in vivo, where the average number of c-mycERTAM transcript copies per CTX0E03 cell was calculated to be 6.9 (SEM = 3.4) at 1-week and 7.7 (SEM = 2.5) at 4-weeks (Figure 2C). The number of CTX0E03 cells, the number c-mycERTAM transcripts calculated per tissue section and the resultant number of c-mycERTAM transcript copies per CTX0E03 cell, are shown in Table 1. c-MycERTAM transcripts were detected within approximately 50% of the tissue sections containing CTX0E03 cells at both time points. It is important to note, in no instance was a c-mycERTAM transcript signal detected where CTX0E03 cells were absent.
Transgene methylation analysis
Direct modification of the DNA by methylation is an epigenetic mechanism to downregulate or silence gene expression. Using bisulfite sequencing, the methylation status of the CMV transgene promoter was investigated in CTX0E03 cells pre- and post-implantation. The CMV promoter of the transgene contains numerous potential methylation sites within a CpG rich island (Figure 3A). Bisulfite sequencing of gDNA clones taken from control non-implanted CTX0E03 cells showed only 2% of these CpG sites were methylated (Figure 3B). However, the same analysis carried out on clones obtained from the CTX0E03 cell implanted MCAo rat brain samples showed that 86.8% (SEM = 7.1) and 75.0% (SEM = 1.4) of the CpG islands were methylated at 1-week and 4-weeks, respectively (Figure 3B). There was no statistical difference between 1- and 4-weeks, p = 0.14, indicating that the methylation had occurred within the first week and was constant to the 4-week time point. Collectively, only four gDNA transgene promoter clones in vivo were found to be devoid of any methylated sites from a total of 99 analysed; in other words, ~96% of the transgene promoter sequences analysed in vivo where found to contain at least one methylated CpG island.
In vitro characterization
Additional experiments were carried out in vitro to determine if a reduction in transgene transcription leads to a concomitant reduction in translated protein. Analyses were carried out on control CTX0E03 cells and those cultured for 1- and 4-weeks in the absence of growth factors and 4-OHT. In this non growth permissive condition, transgene transcription was found to decrease by 59.6% at 1-week and 73.4% at 4-weeks relative to control by qRT-PCR (Figure 4A). Analysis of c-MycERTAM protein was performed by colocalization of c-Myc and ERα antigen staining by immunocytochemistry (ICC; Figure 4B, C, D, E). The c-Myc and ERα antigens were always found to colocalize in the nucleus of a proportion of CTX0E03 cells, indicating that the antibodies were detecting the c-MycERTAM target (Figure 4E). Immunoreactive cells were counted and expressed as a proportion of total cells. These data showed control CTX0E03 cell cultures were approximately 52.0% positive for c-MycERTAM; whereas, following EGF, bFGF and 4-OHT withdrawal the number of CTX0E03 cells positive for c-MycERTAM were 42.5% at 1-week and 12.8% at 4-weeks (Figure 4B). Western blot analysis using the c-Myc and ERα antibodies demonstrated that total c-MycERTAM protein levels followed more closely the progressive drop observed by gene expression and were reduced by 53.8% at 1-week and 73.0% at 4-weeks following EGF, bFGF, and 4-OHT withdrawal (Figure 4F, G).
The c-mycERTAM immortalization technology has been successfully utilized to derive a clonal human neural stem cell line from fetal cortical brain. This cell line, referred to as CTX0E03, possess biological attributes which are desirable for clinical applications for stroke therapy. Namely, this cell line can be continuously expanded in vitro, and following implantation in MCAo rodent brain, results in sensorimotor recovery in the absence of cell treatment-related histopathology [19, 22]. The in vitro effects of c-mycERTAM in the CTX0E03 cell line have been well characterized. Here we investigated the expression of this transgene following implantation of CTX0E03 cells into MCAo rat brain.
In this paper we report a novel method to examine absolute gene expression within human cells implanted into rodent brain. In this example, we analyzed the number of c-mycERTAM transcript copies per CTX0E03 cell both in vitro and in vivo. The calculated c-mycERTAM copies per CTX0E03 cell prepared directly from fresh culture (242.3; SEM = 47.8), cell suspension prior to implantation (215.7; SEM = 13.2) or immediately following implantation (236.9; SEM = 7.8) had comparable values. This validated that the assays employed were CTX0E03 cell specific and the rodent brain background did not cause any interference. Using these established assays, c-mycERTAM transgene transcription was analyzed in the surviving CTX0E03 cell population at 1- and 4-weeks post-implantation in MCAo rodent brain. At both time points there was a substantial reduction in the calculated number of c-mycERTAM transcript copies per CTX0E03 cell detected.
This molecular biological approach provided many advantages over immunohistochemistry and in situ hybridization techniques. The results obtained by RT-PCR and PCR were quantitative. Immunohistochemistry or in situ hybridization techniques do not permit the quantitative assessment of c-mycERTAM levels within a given cell. In addition, the sensitivity of molecular biological techniques were defined, as a single CTX0E03 cell and ten copies of c-mycERTAM per reaction, respectively; whereas, this level of sensitivity would have been difficult, if not impossible, to achieve by immunohistochemistry or in situ hybridization techniques. Our in vivo samples were processed rapidly, immediately after harvesting, thus capturing the most accurate data. Furthermore, from a practical perspective this molecular biological approach analyzed all CTX0E03 cells present in the rodent brain, whereas, histological preparation methods would require a large number of sections to analyze all cells present. Although the average transgene expression significantly decreased in vivo, we cannot exclude the possibility that the expression observed may have arisen from a limited number of CTX0E03 cells. However, the silencing of c-mycERTAM expression observed in vivo is consistent with the absence of tumor formation derived from CTX0E03 cells when implanted in vivo [19, 22].
Transgene silencing can occur at a transcriptional or post-transcriptional level. Long-term transcriptional silencing of retrovirus-delivered genes has been shown largely to result from methylation of the cytosine nucleotides within the promoter regions . The factors responsible for DNA methylation is reviewed in detail elsewhere . As the c-mycERTAM transgene was delivered into the CTX0E03 cell line using a retrovirus, it was reasonable to speculate that transgene silencing had occurred through methylation of CpG islands within the transgene promoter region. Bisulfite DNA sequencing was used to determine the methylation status of the CMV promoter region of the c-mycERTAM transgene within CTX0E03 cells. In culture, only 6 of the total CpG sites screened were found to be methylated. In the samples prepared from CTX0E03 grafted MCAo rodent brain 62 to 100% of the sites were methylated. These data unequivocally show that c-mycERTAM expression is silenced at a transcriptional level in vivo as a result of DNA methylation within the CMV transgene promoter region.
The c-mycERTAM technology acts at a protein rather than a transgene expression level. To mitigate the risk of the technology following intracerebral implantation of CTX0E03 cells it was important to investigate if c-mycERTAM transcription level was a predictive measure of the recombinant protein level. Western blot analysis of the in vivo samples proved impossible because the c-MycERTAM protein would be too dilute to detect in whole brain extracts. In addition, IHC analysis of the in vivo samples was impractical because of the substantial number of sections required to perform a global analysis of c-MycERTAM protein expression. To overcome these challenges we developed and in vitro model of c-mycERTAM silencing in CTX0E03 cells. The kinetics of transgene silencing in vitro was slower than that observed in vivo, which provided the ideal cell culture model to directly compare the progressive decline in c-mycERTAM transcription with the translated protein level. Although we observed a decrease in the number of c-mycERTAM positive cells by ICC, the relative percentage of positive cells did not closely follow relative transgene expression levels. These ICC findings further highlight the drawback of histological approaches because the cells were scored positive independent of the quantity of c-MycERTAM protein present within the cell. On the other hand, when total c-MycERTAM protein levels were measured by western blot they were found to decrease in parallel with transgene transcript level over the 1- to 4-week period. This data indicates that the c-mycERTAM transcript and protein levels are closely linked in CTX0E03 cells.
In conclusion, we have demonstrated that c-mycERTAM transgene expression levels in CTX0E03 cells were significantly reduced in vitro, upon growth factor and 4-OHT withdrawal, and in vivo following implantation. We demonstrated that in vivo transgene silencing occurred through DNA methylation. In addition, the in vitro results showed that c-mycERTAM transcription level was representative of the c-MycERTAM protein level. The data demonstrate that uncontrolled in vivo cell growth arising from c-mycERTAM technology is unlikely based on both the silencing of the c-mycERTAM gene expression reported here and the specific requirement for the 4-OHT ligand to activate the c-MycERTAM protein. Furthermore, these data demonstrate that the retroviral insertion of stable transgene constructs into human neural stem cells with the CMV promoter element is not an inherently unsafe procedure for the production of cellular therapies.
Fetal tissue used to derive CTX0E03 cells was obtained in accordance with nationally (UK and/or USA) approved ethical and legal guidelines. All animal work was performed in accordance with the UK Animals (Scientific Procedures) Act (1986) and approved by the local animal Ethical Review Committee.
Derivation of CTX0E03
The CTX0E03 clonal cell line was derived from human fetal brain cortical tissue of 12 weeks' gestation, as described previously . Briefly, a mixed culture was initiated from the dissociated cortex tissue and was infected with an amphotropic replication-incompetent retroviral vector (pLNCX-2; Clontech) encoding the c-mycERTAM transgene. The CTX0E03 clonal cell line was isolated using a ring cloning method. The CTX0E03 cells were routinely cultured as a monolayer on mouse laminin (Trevigen, AMS Biotechnology, UK) freshly coated flasks in serum free medium (RMM) containing the growth factor supplements 10 ng/ml bFGF (Peprotech), 20 ng/ml EGF (Peprotech), and 100 nM 4-OHT (Sigma). All experiments were carried out using CTX0E03 cells between passage number 33 to 37, which corresponds to a population doubling level (PDL) ranging between 65 to 75.
MCAo and cell grafting
Male Sprague-Dawley rats (Charles River) were group housed with food and water ad libitum. Briefly, animals were subjected to 60 minutes of unilateral MCAo initiated under halothane anesthesia . At 50 minutes into the occlusion, animals were evaluated for behavioral dysfunction (forelimb flexion and contralateral circling behavior). Animals that did not demonstrate dysfunction were removed from the study.
CTX0E03 cells were harvested and suspended at a concentration of ~50,000 cells/μl in HBSS-NAC (HBSS without calcium, magnesium and containing 0.5 mM N-acetyl cysteine; Sigma) and implanted 4-weeks ± 3 days after the occlusion. Each grafted animal received two 4.5 μl bolus injections (approximately 225,000 cells/site with control lesioned animals receiving vehicle only) over 68 sec with 4 min rest before withdrawal. Coordinates from bregma were as follows: Site 1) AP 0.0 mm, L -3.6 mm, V -5.5 mm (from skull surface at bregma); and Site 2) AP 0.0 mm, L +3.6 mm, V -5.5 mm (from skull surface at bregma). Animal brains were collected at 1-week (6 grafted + 2 non-grafted controls) or 4-weeks (6 grafted + 3 non-grafted controls) post-implantation. All animals were administered Cyclosporin A (20 mg/kg, Sandoz Pharmaceuticals) in cremaphore L (Sigma) a day prior to grafting, the day of grafting and then three times weekly for the remaining duration of the study. In addition, Methylprednisolone (Pharmacia Upjohn) was administered at 20 mg/kg for the first 14 days, 10 mg/kg for days 15–17 and 5 mg/kg for days 18–19 post-grafting.
Alu sequence assay to detect and quantify CTX0E03 cells
The qPCR Alu assay was carried out using the LightCycler 480 and the Probes Master mix (Roche). Briefly, an average of 250 ng of genomic DNA was amplified using specific primers (Forward-TGAGGCAGGCGAATCGCTTGAA, Reverse-GACGGAGTTTCGCTCTTGTTG) and a FAM-labeled fluorogenic probe (CGCGATCTCGGCTCACTGCAACCTCCATCG) (PrimerDesign) against a conserved region of the human Alu-Sq sequence (Accession number U14573). The PCR was preformed under the following conditions: 95°C for 30 seconds, followed by 45 cycles of 95°C for 15 s, 58°C for 30 s, 72°C for 15 s. Quantification of the human CTX0E03 DNA in rat tissue was based on a standard curve using serial dilutions that ranged from 1 to 10000 CTX0E03 cells, calculated on the assumption that one human cell contains 6.6 pg of gDNA . The standard curve was performed in the presence of 250 ng of rat gDNA.
CTX0E03 c-mycERTAM transgene transcription assay
Primers were designed to specifically detect the relative c-mycERTAM transgene transcription level in CTX0E03 cells using the Roche Diagnostics Lightcycler LC480 system. Using SYBR Green Master mix (Roche) and primers (Forward-AAAGGCCCCCAAGGTAGTTA, Reverse- AAGGACAAGGCAGGGCTATT), which amplified the c-myc and estrogen receptor (ER) junction, qPCR was performed under the following conditions: 95°C for 5 s, followed by 45 cycles at 95°C for 10 s, 60°C for 20 s,72°C for 20 s, 82°C for 5 s, measuring the fluorescence. A melt curve analysis was also performed after the assay to check the specificity of the reaction using the following conditions: 95°C for 5 s, 65°C for 60 s (1°C increments) followed by 97°C continuous. In order to carry out absolute quantification of c-mycERTAM transcription, a known concentration standard was required to plot a standard curve. Based on the assumption that CTX0E03 cell contains one genomic copy of the c-mycERTAM transgene  serial dilutions ranging from 10 to 10,000 copies of c-mycERTAM were used per reaction to produce the standard curve. The standard curve was performed in the presence of rat cDNA.
Calculation of c-mycERTAM transcription level in vivo
At 1- or 4-weeks post-implantation, the rat brains were removed, cut into 50–250 mg sections and snap frozen in liquid nitrogen. The gDNA and total RNA was then sequentially isolated from each tissue piece using the AllPrep DNA/RNA mini kit (Qiagen). Four tissue sections were processed per rat brain (i.e. two tissue sections encompassing each injection tract). In brief, the tissue samples were homogenised in the supplied lysis buffer according to sample weight. The lysed sample was processed first through an AllPrep DNA spin column, to isolate the gDNA, and subsequently through an RNeasy spin column to selectively isolate RNA. The gDNA and total RNA samples (1 μl/reaction) were then analyzed by qPCR for Alu signal and qRT-PCR for c-mycERTAM, respectively. Based on the Alu signal, the number of CTX0E03 cells present per reaction was calculated from the standard curve. Similarly, the number of c-mycERTAM transcripts present per reaction was interpolated from the c-mycERTAM copy number standard curve. A calculation was then carried out to correct for the amount analyzed and the total volume of tissue sample lysate (for example, 1 μl from a total of 650 μl). The corrected figures were then expressed as the number of c-mycERTAM transcripts present over the number of CTX0E03 cells present in each tissue section. Standard error of the mean was calculated for all tissue sections found to contain cells (Microsoft Excel version 2003).
Transgene methylation analysis by bisulfite sequencing
Bisulfite treatment of DNA followed by sequencing was used to determine the endogenous transgene promoter pattern of methylation in CTX0E03 cells. Methylation is implicated in repression of genetic activity and involves the addition of a methyl group to the carbon-5 position of cytosine residues of the dinucleotide CpG. Bisulfite sequencing is a technique used to identify specific gDNA methylation sites based on the fact that treatment of DNA with bisulfite converts cytosine residues to thymidine, but leaves 5-methylcytosine residues unaffected. Bisulfite treatment thus introduces a specific change in the DNA sequence which is dependent on the methylation status of individual cytosine residues. A bisulfite reaction was performed using Epitect Bisulfite (Qiagen). Up to 2 μg of genomic DNA was used for conversion with the bisulfite reagent. Bisulfite-converted DNA was used as a template for PCR amplification. PCR primers were designed using the web program METHPRIMER (; http://www.urogene.org/methprimer/index1.html). Primers used were: Forward – GGGAGTTTGTTTTGGTATTAAAATTAA and Reverse – ACTACTACTAATAAAAATTCTCCTCCTC. PCR conditions were 94°C for 5 minutes, 30 cycles of 94°C for 30 seconds, 60°C for 1 min, and 72°C for 30 seconds followed by 10 min at 72°C. PCR fragments were cloned into TA-cloning vector using TOPO TA Cloning Kit for Sequencing (Invitrogen). Ten individual clones were sequenced by GATC Biotech (Germany) using the T3 universal PCR primers. The resulting sequences were analyzed using blast software http://blast.ncbi.nlm.nih.gov/Blast.cgi. Sequence analysis that identified an unchanged cytosine base (i.e. protected from the bisulfite conversion reaction) was considered to be methylated, but a cytosine conversion to thymidine in the sequence indicated no methylation.
In vitro characterisation: western blot and immunocytochemical analysis
In vitro, CTX0E03 cell samples were prepared by maintaining the cells in non-growth permitting medium alone, without the addition of EGF, bFGF, and 4-OHT, for 1- and 4-weeks. Western blot analysis for c-mycERTAM protein in CTX0E03 cells was carried out using the whole-cell lysate. To prepare cell lysate, CTX0E03 cell monolayers in a T75 flask were rinsed with cold PBS (4°C), lysed with 750 μl 1× SDS Sample Buffer and dithiothreitol (DTT) Reducing Agent (PAGEgel Inc, AMS Biotechnology, UK), and collected in a 1.5 ml centrifuge tube. Samples were triturated multiple times to lyse and shear the sample, heated at 100°C for 2 min and centrifuged. Cell lysates were loaded onto a 4%–20% Tris-Tricine gel (PAGEgel Inc, AMS Biotechnology, UK), 10 μl per well. After electrophoresis, the protein was transferred onto a nitrocellulose membrane with 0.2 μm pore size by electroelution. Immunodetection was performed with a rabbit anti-ERα polyclonal or a mouse anti-c-Myc monoclonal antibody (Santa Cruz Biotechnology Inc, both used at 1:100). Transgene product was detected using horseradish peroxidase-conjugated anti rabbit-IgG (Cell Signaling Technology, 1:2000) or anti mouse-IgG (Pierce Biotechnology Inc., 1:800) secondary antibodies, as appropriate. The nitrocellulose membrane was then processed using chemiluminescence detection reagents (Thermo scientific). The blots were then stripped and reprobed using anti-α-tubulin (Sigma, 1:1000) to act as an internal loading level standard. Western blot images were captured using BioRad FluorS Imaging Unit and densitometry carried out using Scion Image software (Scion Corporation, version Alpha 126.96.36.199, USA).
Immunocytochemistry was carried out on CTX0E03 cells fixed in a 96-well plate (BD) using 4% PFA/4% sucrose in PBS for 15 min after 3 days growth (control) and following 1- and 4-weeks in medium containing no growth factors (EGF, bFGF) or 4-OHT. Anti-c-myc (1:100) and anti-ERα (1:500) were incubated in 1xPBS containing 1% normal goat serum (Vector laboratories) overnight at room temperature. After rinsing, the CTX0E03 cells were incubated for 1.5 h at room temperature using anti-mouse conjugated Alexa Fluor 488 (Invitrogen, 1:2000) for c-myc and anti-rabbit conjugated Alexa Fluor 568 (Invitrogen, 1:2500) for ERα. CTX0E03 cells were then counterstained by incubating with Hoechst 33342 (Sigma, 1 μM) for 2 min. Quantification of c-myc and ERα was carried out by manual counting of three representative fields using an Olympus IX70 fluorescent microscope.
Wong AM, Hodges H, Horsburgh K: Neural stem cell grafts reduce the extent of neuronal damage in a mouse model of global ischaemia. Brain Res. 2005, 1063 (2): 140-150. 10.1016/j.brainres.2005.09.049.
Hodges H, Nelson A, Virley D, Kershaw TR, Sinden JD: Cognitive deficits induced by global cerebral ischaemia: prospects for transplant therapy. Pharmacol Biochem Behav. 1997, 56 (4): 763-780. 10.1016/S0091-3057(96)00424-8.
Sinden JD, Rashid-Doubell F, Kershaw TR, Nelson A, Chadwick A, Jat PS, Noble MD, Hodges H, Gray JA: Recovery of spatial learning by grafts of a conditionally immortalized hippocampal neuroepithelial cell line into the ischaemia-lesioned hippocampus. Neuroscience. 1997, 81 (3): 599-608. 10.1016/S0306-4522(97)00330-8.
Modo M, Stroemer RP, Tang E, Patel S, Hodges H: Effects of implantation site of stem cell grafts on behavioral recovery from stroke damage. Stroke. 2002, 33 (9): 2270-2278. 10.1161/01.STR.0000027693.50675.C5.
Veizovic T, Beech JS, Stroemer RP, Watson WP, Hodges H: Resolution of stroke deficits following contralateral grafts of conditionally immortal neuroepithelial stem cells. Stroke. 2001, 32 (4): 1012-1019.
De Filippis L, Ferrari D, Rota Nodari L, Amati B, Snyder E, Vescovi AL: Immortalization of human neural stem cells with the c-myc mutant T58A. PLoS ONE. 2008, 3 (10): e3310-10.1371/journal.pone.0003310.
Bai Y, Hu Q, Li X, Wang Y, Lin C, Shen L, Li L: Telomerase immortalization of human neural progenitor cells. Neuroreport. 2004, 15 (2): 245-249. 10.1097/00001756-200402090-00006.
Villa A, Navarro-Galve B, Bueno C, Franco S, Blasco MA, Martinez-Serrano A: Long-term molecular and cellular stability of human neural stem cell lines. Exp Cell Res. 2004, 294 (2): 559-570. 10.1016/j.yexcr.2003.11.025.
Donato R, Miljan EA, Hines SJ, Aouabdi S, Pollock K, Patel S, Edwards FA, Sinden JD: Differential development of neuronal physiological responsiveness in two human neural stem cell lines. BMC Neurosci. 2007, 8: 36-10.1186/1471-2202-8-36.
De Filippis L, Lamorte G, Snyder EY, Malgaroli A, Vescovi AL: A novel, immortal, and multipotent human neural stem cell line generating functional neurons and oligodendrocytes. Stem Cells. 2007, 25 (9): 2312-2321. 10.1634/stemcells.2007-0040.
Cho T, Bae JH, Choi HB, Kim SS, McLarnon JG, Suh-Kim H, Kim SU, Min CK: Human neural stem cells: electrophysiological properties of voltage-gated ion channels. Neuroreport. 2002, 13 (11): 1447-1452. 10.1097/00001756-200208070-00020.
Ryder EF, Snyder EY, Cepko CL: Establishment and characterization of multipotent neural cell lines using retrovirus vector-mediated oncogene transfer. J Neurobiol. 1990, 21 (2): 356-375. 10.1002/neu.480210209.
Snyder EY, Deitcher DL, Walsh C, Arnold-Aldea S, Hartwieg EA, Cepko CL: Multipotent neural cell lines can engraft and participate in development of mouse cerebellum. Cell. 1992, 68 (1): 33-51. 10.1016/0092-8674(92)90204-P.
Rao MS, Anderson DJ: Immortalization and controlled in vitro differentiation of murine multipotent neural crest stem cells. J Neurobiol. 1997, 32 (7): 722-746. 10.1002/(SICI)1097-4695(19970620)32:7<722::AID-NEU7>3.0.CO;2-6.
Jung M, Kramer EM, Muller T, Antonicek H, Trotter J: Novel pluripotential neural progenitor lines exhibiting rapid controlled differentiation to neurotransmitter receptor-expressing neurons and glia. Eur J Neurosci. 1998, 10 (10): 3246-3256. 10.1046/j.1460-9568.1998.00344.x.
Villa A, Snyder EY, Vescovi A, Martinez-Serrano A: Establishment and properties of a growth factor-dependent, perpetual neural stem cell line from the human CNS. Exp Neurol. 2000, 161 (1): 67-84. 10.1006/exnr.1999.7237.
Nakafuku M, Nakamura S: Establishment and characterization of a multipotential neural cell line that can conditionally generate neurons, astrocytes, and oligodendrocytes in vitro. J Neurosci Res. 1995, 41 (2): 153-168. 10.1002/jnr.490410203.
Miljan EA, Hines SJ, Pande P, Corteling RL, Hicks C, Zbarsky V, Umachandran M, Sowinski P, Richardson S, Tang E, et al.: Implantation of c-mycERTAM immortalized human mesencephalic derived clonal cell lines ameliorates behaviour dysfunction in a rat model of Parkinson disease. Stem Cells Dev. 2008, 18 (2): 307-319. 10.1089/scd.2008.0078.
Pollock K, Stroemer P, Patel S, Stevanato L, Hope A, Miljan E, Dong Z, Hodges H, Price J, Sinden JD: A conditionally immortal clonal stem cell line from human cortical neuroepithelium for the treatment of ischemic stroke. Exp Neurol. 2006, 199 (1): 143-155. 10.1016/j.expneurol.2005.12.011.
Maurer J, Fuchs S, Jager R, Kurz B, Sommer L, Schorle H: Establishment and controlled differentiation of neural crest stem cell lines using conditional transgenesis. Differentiation. 2007, 75 (7): 580-591. 10.1111/j.1432-0436.2007.00164.x.
Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI: A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res. 1995, 23 (10): 1686-1690. 10.1093/nar/23.10.1686.
Stroemer P, Patel S, Hope A, Oliveira C, Pollock K, Sinden J: The Neural Stem Cell Line CTX0E03 Promotes Behavioral Recovery and Endogenous Neurogenesis after Experimental Stroke in a Dose-Dependent Fashion. Neurorehab Neural Repair.
Zhang F, Thornhill SI, Howe SJ, Ulaganathan M, Schambach A, Sinclair J, Kinnon C, Gaspar HB, Antoniou M, Thrasher AJ: Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells. Blood. 2007, 110 (5): 1448-1457. 10.1182/blood-2006-12-060814.
Lee HJ, Kim KS, Kim EJ, Choi HB, Lee KH, Park IH, Ko Y, Jeong SW, Kim SU: Brain transplantation of immortalized human neural stem cells promotes functional recovery in mouse intracerebral hemorrhage stroke model. Stem Cells. 2007, 25 (5): 1204-1212. 10.1634/stemcells.2006-0409.
Nicklas JA, Buel E: Development of an Alu-based, real-time PCR method for quantitation of human DNA in forensic samples. J Forensic Sci. 2003, 48 (5): 936-944.
Schneider T, Osl F, Friess T, Stockinger H, Scheuer WV: Quantification of human Alu sequences by real-time PCR – an improved method to measure therapeutic efficacy of anti-metastatic drugs in human xenotransplants. Clin Exp Metastasis. 2002, 19 (7): 571-582. 10.1023/A:1020992411420.
Lavie L, Kitova M, Maldener E, Meese E, Mayer J: CpG methylation directly regulates transcriptional activity of the human endogenous retrovirus family HERV-K(HML-2). J Virol. 2005, 79 (2): 876-883. 10.1128/JVI.79.2.876-883.2005.
Strathdee G, Brown R: Aberrant DNA methylation in cancer: potential clinical interventions. Expert Rev Mol Med. 2002, 4 (4): 1-17. 10.1017/S1462399402004222.
Longa EZ, Weinstein PR, Carlson S, Cummins R: Reversible middle cerebral artery occlusion without craniectomy in rats. Stroke. 1989, 20 (1): 84-91.
Applied_Biosystems: Creating standard curves with genomic DNA or plasmid DNA templates for use in quantitative PCR. [http://www.appliedbiosystems.com/support/tutorials/pdf/quant_pcr.pdf]
Li LC, Dahiya R: MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002, 18 (11): 1427-1431. 10.1093/bioinformatics/18.11.1427.
Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, Lightfoot S, Menzel W, Granzow M, Ragg T: The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol. 2006, 7: 3-10.1186/1471-2199-7-3.
We thank Prof. Jack Price (King's College London, United Kingdom) for his general support and helpful discussions. In addition, our gratitude extends to Dr. Aaron Jeffries (King's College London, United Kingdom) for advice and guidance on DNA methylation analysis; and to PrimerDesign for their help in developing the Alu primers. We also extend our thanks to Susan Hines (Imperial College London, United Kingdom) and Dr. Marc Oliver Baradez (Laboratory of the Government Chemist, LGC, United Kingdom) for their kind assistance in the preparation of the cells used in this study. This study was supported and designed by ReNeuron (RENE.L) who where involved in study design, data collection, analysis, and interpretation, as well as manuscript preparation and decision to submit for publication.
EM, LS, AH and JS conceived the experiments. LS, EM, RC, JH and PS designed and performed the experiments and analyzed the data. All authors contributed to the preparation of the written manuscript.